米格列奈钙对初诊2型糖尿病患者血浆成纤维细胞生长因子21水平的影响  

Effect of mitiglinide calcium on fasting plasma fibroblast growth factor-21 level in patients with newly diagnosed type 2 diabetes mellitus

作　　者：范莹莹[1] 杨刚毅[1] 李伶[2] 李志勇[3] 廖涌 程春瑞[1] 汤世国[1] 李生兵[1] 李娜[1] 王毅[5] 

机构地区：[1]重庆医科大学附属第二医院内分泌科,400010 [2]重庆医科大学检验系临床生化教研室和教育部实验诊断重点实验室 [3]重庆医科大学附属永川医院内分泌科 [4]重庆武警总队医院内分泌科 [5]重庆市第九人民医院内分泌科

出　　处：《中华内分泌代谢杂志》2012年第2期143-145,共3页Chinese Journal of Endocrinology and Metabolism

基　　金：国家自然科学基金项目（30771037,30871199,30971388,81070640）

摘　　要：82例初诊2型糖尿病,给予口服米格列奈钙片16周,测定治疗前后血浆成纤维细胞生长因子21（FGF-21）水平,分析血浆FGF-21水平与体重指数、血脂、空腹血糖、血浆胰岛素、胰岛素抵抗指数和胰岛β细胞分泌指数等水平的关系.米格列奈钙能有效降低2型糖尿病患者血浆FGF-21水平,血浆FGF-21水平变化可能与2型糖尿病的发生发展有关.Eighty-two newly-diagnosed type 2 diabetic patients with poor glycemic control were treated by mitiglinide calcium for 16 weeks.Plasma fibroblast growth factor-21 （ FGF-21 ） level were evaluated.The relationship of plasma FGF-21 levels with body mass index,body fat,waist-to-hip ratio,lipid,blood glucose,HbA1c,and free fatty-acid were analyzed.Plasma FGF-21 was decreased significantly by treatment with mitiglinide calcium in type 2 diabetic patients,and it may play a role in the pathogenesis of type 2 diabetes mellitus.

关 键 词：米格列奈钙 糖尿病 2型 成纤维细胞生长因子21 

分 类 号：R587.1[医药卫生—内分泌]